<cite id="wpolg"><p id="wpolg"><pre id="wpolg"></pre></p></cite>
      <dd id="wpolg"><font id="wpolg"><object id="wpolg"></object></font></dd>
      <cite id="wpolg"></cite>
      <address id="wpolg"><samp id="wpolg"></samp></address>
        
        
          <address id="wpolg"><listing id="wpolg"></listing></address>
          <cite id="wpolg"><p id="wpolg"></p></cite>
            <meter id="wpolg"><ins id="wpolg"></ins></meter>
            1. 人琴棋牌

              Maruho Co.,Ltd. Corporate Information
              11/12

              Major ProductsNagahama Plant2008Opened Düsseldorf Representative Office(active until 2013)2009Opened Tokyo Development OfficeOpened New York Office(active until 2011)2010Nagahama Plant completed2011Announced Long-Term Vision 2011, “Excellence in Dermatology”Established Maruho North America Inc.(MNAI) as a wholly owned subsidiary(active until 2015)2013Established Maruho Deutschland GmbH as a wholly owned subsidiaryAcquired Maruho Hatsujyo Kogyo Co., Ltd. as a subsidiary through share acquisition2014Established Tateyama Pharmaceutical Factory Co., Ltd. as a subsidiary2015Integrated MNAI into Cutanea2016Maruho Co., Ltd. and Maruho’s Founders, the Takagi Family, jointly established the Maruho Takagi Dermatology Foundation.(From August it was certified as a Public Interest Incorporated Foundation by the Japanese Government)2012Acquired Cutanea Life Sciences, Inc.(Cutanea) in the US as a wholly owned subsidiaryEstablished Maruho Europe Ltd. as a wholly owned subsidiary(active until 2015)Agent for asthma AsthmolysinAnti-hemorrhoidal preparation PosterisanNon-specific desensitizing agent Paspat Percutaneous InjectionAnticoagulant and blood circulation promotion agent HirudoidAsthmolysin Capsules, additional formulation of AsthmolysinHigh-potency multiple digestive enzyme preparation CombizymNon-specific desensitizing agent Paspat Intracutaneous InjectionAgent for dermal disease EksalbPosterisan forte Ointment, additional formulation of PosterisanAsthmolysin Suppository, additional formulation of AsthmolysinTransdermal multiple anti-inflammatory Mobilat OintmentArticular cartilage protective agent ArteparonTopical cortical hormone Voalla Ointment and Voalla CreamDisposable dermal trephine DispopunchAnti-inflammatory/fever-reducing analgesic Minalfen TabletsRecombinant interferon gamma Biogamma Injection 200Hirudoid Soft, additional formulation of HirudoidJoint function improving agent HyalosPosterisan F Suppository, additional formulation of PosterisanTransdermal therapeutic system bronchodilator Hokunalin TapeNon-chemical debriding agent Bromelain OintmentAnti-virus agent Casal CreamNatural skincare series 2eHirudoid Lotion, additional formulation of HirudoidAgent for keratosis such as psoriasis vulgaris Oxarol OintmentOral penem antibiotic Farom Tablets and Farom Dry Syrup for Pediatric UseAnthelmintic (anti-parasitic) STROMECTOL TabletsOral allylamine antifungal agent Nedoril TabletsLocal anesthetic patch PenlesOxarol Lotion, additional formulation of OxarolAgent for pressure ulcers/skin ulcers Iodocoat OintmentAnti-herpes virus agent Famvir TabletsAdditional indication of palmoplantar pustulosis for Oxarol formulationsFarom Tablets and Farom Dry Syrup for Pediatic Use retained marketing approvalPressure ulcers/skin ulcers treatment Actosin OintmentFarom Dry Syrup for Pediatric Use Additional 0.5g sachetNatural skincare series for infants 2e Baby PlusAdditional indication of for herpes simplex approved for Famvir TabletsSkincare series iniksHuman anti-human IL-17A monoclonal antibody CosentyxAcne vulgaris treatment agent BEPIO GelQuinolone anti-microbial topical treatment Zebiax LotionPsoriasis vulgaris treatment agent Marduox OintmentAcne vulgaris treatment agent Differin Gelinfantile hemangioma treatment Hemangiol Syrup for PediatricAcne vulgaris treatment agent Epiduo GelSkincare iniks UV protection and iniks skincare kitTopical scalp psoriasis treatment Comclo Shampoo Epiduo Gel retained marketing approvalAnti-herpes virus agent Amenalief TabletsProtopic Ointment retained marketing approval1951-19771953-1954-20011954-1957-19941959-20031960-20011962-1965-1968-20021968-20061984-19931986-1987-20001988-20081990-1992-20061996-1998-20171999-2000-2000-20142001-2005-2006-2007-2008-2009-2010-2011-2011-20142012-2013-2014-2015-2016-2017-Additional indication of asteatosis approved for Hirudoid; efficacy classification changed to “blood-flow acelerative/skin-moisturizing agent”Antifungal agents Astat Cream, Astat Solution, and Astat Ointment retained marketing approvalAdditional indication of pain relief in laser irradiation treatment of the skin approved for Penles TapeAnti-atopic dermatitis agent Protopic Ointment 0.1% and Protopic Ointment 0.03% for Pediatric Use(2011.4-2014.3 sales promotion only)Additional indication of pain following removal of molluscum contagiosum approved for Penles Tape10

              元のページ  ../index.html#11

              このブックを見る

              人琴棋牌